Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Postmarketing surveillance of the safety of cimetidine: 12 month mortality report. Br Med J (Clin Res Ed) 1983 May 28;286(6379):1713–1716. doi: 10.1136/bmj.286.6379.1713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Inman W. H., Rawson N. S. Erythromycin estolate and jaundice. Br Med J (Clin Res Ed) 1983 Jun 18;286(6382):1954–1955. doi: 10.1136/bmj.286.6382.1954. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lawson D. H., Henry D. A. Monitoring adverse reactions to new drugs: "restricted release" or "monitored release"? Br Med J. 1977 Mar 12;1(6062):691–692. doi: 10.1136/bmj.1.6062.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stolley P. D. The use of vital and morbidity statistics for the detection of adverse drug reactions and for monitoring of drug safety. J Clin Pharmacol. 1982 Nov-Dec;22(11-12):499–504. doi: 10.1002/j.1552-4604.1982.tb02642.x. [DOI] [PubMed] [Google Scholar]
- Venning G. R. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems. Br Med J (Clin Res Ed) 1983 Feb 5;286(6363):458–460. doi: 10.1136/bmj.286.6363.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wilson A. B. Post-marketing surveillance of adverse reactions to new medicines. Br Med J. 1977 Oct 15;2(6093):1001–1003. doi: 10.1136/bmj.2.6093.1001. [DOI] [PMC free article] [PubMed] [Google Scholar]